Crizotinib and Orfadin (Nitisinone Oral Suspension)

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with crizotinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by crizotinib. The interaction has been studied with midazolam, a probe substrate for CYP450 3A4. In study patients, administration of oral midazolam during treatment with crizotinib (250 mg twice daily for 28 days) resulted in a 3.7-fold increase in mean midazolam systemic exposure (AUC) compared to administration of midazolam alone, suggesting that crizotinib is a moderate inhibitor of CYP450 3A4. MANAGEMENT: Caution is advised when crizotinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever crizotinib is added to or withdrawn from therapy. Concomitant use of crizotinib and substrates of CYP450 3A4 with a narrow therapeutic index (e.g., antiarrhythmic agents, benzodiazepines, ergot derivatives, immunosuppressants, vinca alkaloids) should be avoided if possible. References "Product Information. Xalkori (crizotinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.

MONITOR: Coadministration with crizotinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by crizotinib. The interaction has been studied with midazolam, a probe substrate for CYP450 3A4. In study patients, administration of oral midazolam during treatment with crizotinib (250 mg twice daily for 28 days) resulted in a 3.7-fold increase in mean midazolam systemic exposure (AUC) compared to administration of midazolam alone, suggesting that crizotinib is a moderate inhibitor of CYP450 3A4.

MANAGEMENT: Caution is advised when crizotinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever crizotinib is added to or withdrawn from therapy. Concomitant use of crizotinib and substrates of CYP450 3A4 with a narrow therapeutic index (e.g., antiarrhythmic agents, benzodiazepines, ergot derivatives, immunosuppressants, vinca alkaloids) should be avoided if possible.

Crizotinib

Generic Name: crizotinib

Brand name: Xalkori

Synonyms: n.a.

What is Crizotinib?

Orfadin (Nitisinone Oral Suspension)

Generic Name: nitisinone

Brand name: Orfadin, Nityr

Synonyms: Orfadin

What is Orfadin (Nitisinone Oral Suspension)?